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BACKGROUND: Complete resection of metastases can result in cure for selected patients with metastatic colorectal cancer.
METHODS: First BEAT evaluated the safety of bevacizumab with first-line chemotherapy in 1914 patients. Prospectively collected data
from 225 patients who underwent curative-intent surgery were analysed, including an exploratory comparison of resection rate in
patients treated with different regimens. NO16966 compared efficacy of oxaliplatin-based chemotherapy plus bevacizumab or
placebo in 1400 patients. A retrospective analysis of resection rate was undertaken.
RESULTS: In First BEAT, 225 out of 1914 patients (11.8%) underwent curative-intent surgery at median 64 days (range 42–100) after
the last dose of bevacizumab. R0 resection was achieved in 173 out of 225 patients (76.9%). There were no surgery-related deaths
and serious post-operative complications were uncommon, with grade 3/4 bleeding and wound-healing events reported in 0.4% and
1.8%, respectively. Resection rates were highest in patients receiving oxaliplatin-based combination chemotherapy (P¼0.002),
possibly confounded by patient selection. In NO16966, 44 out of 699 patients treated with bevacizumab (6.3%) and 34 out of 701
patients treated with placebo (4.9%) underwent R0 metastasectomy (P¼0.24).
CONCLUSIONS: The rate of serious post-operative complications in First BEAT was comparable to historical controls without
bevacizumab. In NO16966, there were no statistically significant differences in resection rates or overall survival in patients treated
with bevacizumab vs placebo.
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The addition of oxaliplatin and irinotecan to 5-fluorouracil (5-FU)
in metastatic colorectal cancer (mCRC) has improved patient
survival and the chance of downsizing initially unresectable
metastatic disease, to allow curative-intent surgery. Although the
optimal management of liver metastases which are resectable at
presentation has not been definitively established, the prospective,
randomised controlled European Organisation for Research and
Treatment of Cancer (EORTC), Belgium/Intergroup trial 40983 of
peri-operative 5-FU and oxaliplatin (FOLFOX4) vs surgery alone
demonstrated a statistically significant difference in progression-
free survival (PFS) in the subgroups of eligible and resected
patients, although not the intention to treat (ITT) population
(Nordlinger et al, 2008), supporting some role for peri-operative
chemotherapy. Unfortunately, the trial did not meet the primary
endpoint and neither distinguished between synchronous vs
metachronous presentations, nor stratified for the length of
disease-free interval in the latter group. However, peri-operative
chemotherapy is a widely accepted strategy, in particular for
synchronous presentations, or metachronous presentations occur-
ring soon after treatment of the primary tumour. An alternative
strategy for patients with resectable liver metastases is the use
of adjuvant chemotherapy, supported by a recently published
combined analysis of the Federation Francophone de Cancerologie
Digestive (FFCD) Trial 9002 and the EORTC/National Cancer
Institute of Canada Clinical Trials Group (NCICCTG), Canada/
Gruppo Italiano di Valutazione Interventi in Oncologia phase-III
trials. The analysis included 278 patients and showed a moderate,
but non-statistically significant benefit for adjuvant bolus 5-FU
plus leucovorin over surgery alone for PFS (27.9 vs 18.8 months,
hazard ratio (HR) 1.32; 95% confidence interval (CI), 1.00–1.76;
P¼0.058) and overall survival (OS) (62.2 vs 47.3 months, HR 1.32;
95% CI, 0.95–1.82; P¼0.095) (Mitry et al, 2008).
A newer treatment paradigm has been proposed for highly
selected patients with unresectable liver-only metastases in such
patients, primary chemotherapy may allow a proportion, in
whom adequate downsizing is achieved, to undergo subsequent
resection (Leichman, 2007). These patients, by the estimates of
some investigators, may comprise up to a quarter of patients
presenting with mCRC (Adam et al, 2001, 2004). In one study,
patients who underwent hepatic resection after conversion
chemotherapy had a reduced OS compared with those with
primary resectable disease (Adam et al, 2004); however, with a
median follow up of 48.7 months, 18% remained free of disease, Received 7 April 2009; revised 13 July 2009; accepted 23 July 2009
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sand so are potentially cured (Watkins et al, 2007). The median OS
from mCRC treated with 5-FU, oxaliplatin and irinotecan has
reached over 20 months, whether given concomitantly (Falcone
et al, 2007) or sequentially (Tournigand et al, 2004), but despite
this, o5% of unresectable patients will live up to 5-years with
chemotherapy alone (Chua and Cunningham, 2006). In contrast,
the reported 5-year survival of the highly selected group of patients
with initially unresectable liver-only disease treated with
conversion chemotherapy then surgery ranges from 33–50%
(Giacchetti et al, 1999; Adam et al, 2001, 2004). Inevitably, some
patients will not benefit from metastasectomy after conversion
chemotherapy and identifying these patients is vital for preventing
futile surgery.
Prospective evaluation of conversion chemotherapy for patients
with liver-only, primarily unresectable disease has been under-
taken in the phase-II setting, with response rates (RR) of 48–71%
and R0 resection rate of 26–41% in these selected populations
(Pozzo et al, 2004; De La Ca ´mara et al, 2004; Alberts et al, 2005;
Ychou et al, 2007), however, high rates of recurrence of up to 73%
were reported (Alberts et al, 2005; Giacchetti et al, 1999). Resection
rate has also been prospectively evaluated within phase-II and -III
trials in patients with any-site mCRC, with RR of 33–66% and R0
resection rates of up to 15% reported, despite the unselected
population (Tournigand et al, 2004, 2006; Delaunoit et al, 2005;
Falcone et al, 2007).
The addition of bevacizumab, to first and second line
chemotherapy for mCRC has demonstrated statistically significant
improvements in PFS (Kabbinavar et al, 2003, 2005; Hurwitz et al,
2004; Giantonio et al, 2007; Saltz et al, 2008), and statistically
significant improvement in OS in some studies (Hurwitz et al,
2004; Giantonio et al, 2007). However, there are currently no data
evaluating the role of bevacizumab added to chemotherapy in the
peri-operative setting. We present here our evaluation of this topic
in two large prospective trials.
MATERIALS AND METHODS
Two large international multicentre studies were included in this
analysis. First bevacizumab expanded access trial (BEAT) added
bevacizumab to investigator’s choice fluoropyrimidine-based
chemotherapy in the first-line treatment of mCRC. This inter-
national trial recruited 1965 patients from 41 countries between
June 2004 and February 2006. Eligible patients were aged at least
18-years old, had histologically confirmed mCRC, had not received
chemotherapy for mCRC previously, were of ECOG performance
status 0–1, with adequate bone marrow, liver and renal function,
without significant proteinuria and were scheduled to receive first-
line fluoropyrimidine-based chemotherapy. Patients who had
undergone major surgery within 28 days, had a serious non-
healing wound or ulcer, a bleeding diathesis, coagulopathy or were
on therapeutic anticoagulation, had uncontrolled hypertension or
clinically significant cardiovascular disease were excluded from the
study.
Safety was the primary endpoint of the trial. This included the
incidence of all reported adverse or serious adverse events, serious
adverse events related to bevacizumab and the targeted adverse
events of gastrointestinal perforation, wound healing complica-
tions, hypertension, proteinuria, bleeding and thromboembolism.
Time to disease progression; defined as the time period from the
start of first-line therapy to investigator assessed disease progres-
sion, and OS; defined as the time period from the start of first-line
therapy to death, were secondary endpoints.
Data for secondary resections (metastasectomy) were prospec-
tively collected in the overall (ITT) population, defined as all
patients who received at least one dose of the study drug,
bevacizumab. The safety of bevacizumab in all patients undergoing
secondary resection was also prospectively examined.
The NO16966 study was designed to show non-inferiority of
capecitabine plus oxaliplatin (XELOX) to FOLFOX4 after the
presentation of the pivotal trial by Hurwitz et al, showing a
survival benefit from adding bevacizumab to first-line combina-
tion chemotherapy with irinotecan and bolus 5-FU/leucovorin
(IFL) for mCRC, the trial was amended to a two-by-two design to
assess the addition of bevacizumab to each combination. Between
February 2004 and February 2005, 1401 patients were randomised
to the four arms of the trial, which met the primary endpoints of
non-inferiority of XELOX to FOLFOX for PFS and superiority of
chemotherapy plus bevacizumab to chemotherapy plus placebo for
PFS. The ITT population (n¼1400) was defined as all patients who
signed the trial consent form and were randomised. Eligibility
criteria for this trial have been published previously.
Secondary resection rate was not a predefined endpoint of the
NO16966 trial and as such, the trial was not powered to detect a
difference in patients treated with or without bevacizumab, but
these data have been retrospectively collected and analysed for the
ITT population. Bevacizumab-related adverse events were pro-
spectively collected in the study, but the rate of peri-operative
complications was not.
For both studies, the protocol was reviewed by an independent
review body and all patients were required to give written,
informed consent.
Statistical methods
First BEAT Resection rates were calculated for the ITT popula-
tion, for curative-intent surgery (the site of surgery was the only
site of disease), R0 resection (complete resection with no residual
disease), all hepatic surgery performed, curative-intent hepatic
surgery and R0 resection rate.
Resection rates were also calculated for the exploratory
subgroups of patients treated with oxaliplatin-based chemotherapy
regimens and irinotecan-based regimens. Fisher’s exact test was
used to compare resection rates. Kaplan–Meier survival curves
were generated for OS in the subgroups of patients undergoing
curative-intent hepatic resection, those undergoing R0 hepatic
resection and the remainder of the ITT population. In addition,
survival curves were generated for the exploratory subgroup of
patients with liver-only metastatic disease who underwent R0
resection vs those who did not.
The log-rank test was used to compare PFS and OS in those
undergoing any surgery, all curative-intent surgery, R0 resections,
hepatic metastasectomy, curative-intent hepatic metastasectomy and
R0 hepatic metastasectomy compared with those that did not, in the
ITT population and the subgroup of patients with liver-only disease.
NO16966 w
2 test comparisons were used for the rates of curative (R0
resection) surgery and curative liver surgery. The log-rank test was
used to compare PFS in patients randomised to receive bevacizumab,
vs those receiving placebo. No additional statistical testing was
applied to the adverse event rates for the bevacizumab comparison,
which have been previously published. Complication rates in patients
who underwent surgery were not collected during the study.
RESULTS
First BEAT
Baseline characteristics for the 1914 patients evaluable for the final
analysis in February 2008 are summarised in Table 1.
ITT population resection rate
Table 2 shows that 225 out of 1914 patients (11.8%) underwent
surgery with curative-intent, of whom R0 resection was achieved in
173 out of 225 patients (76.9%). The median duration of treatment
curative intent surgery in First BEAT and NO16966
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Surgery was undertaken at a median of 64 days after the last dose
of bevacizumab (range 42–100 days).
The surgery comprised of curative-intent hepatic metastasect-
omy in 145 cases (7.6%), with R0 resection reported in 114 out of
145 patients (78.6%). The type of curative-intent surgery under-
taken in the remaining 80 out of 225 patients were not collected.
Of patients who received oxaliplatin-based combination chemo-
therapy (with 5-FU or capecitabine) 153 out of 949 (16.1%)
underwent surgery with curative-intent, whereas 64 out of 662
(9.7%) of patients treated with irinotecan based combinations
underwent surgery. In an exploratory comparison of these
numbers, the difference is statistically significant (P¼0.002). R0
resection was achieved in 116 out of 153 patients (75.8%) that
received oxaliplatin-based chemotherapy and 49 out of 64 patients
(76.6%) that received irinotecan-based combinations.
ITT population OS
The median OS is 21.4 months (95% CI 20.5–22.4 months) in the
1769 patients who did not undergo curative-intent surgery and has
not been reached in the 145 patients who underwent curative-
intent hepatic surgery (HR 0.24, 95% CI 0.17–0.34, Po0.001) or
the 114 patients in whom R0 resection was achieved (HR 0.15, 95%
CI 0.10–0.25, Po0.001). The Kaplan–Meier curves for patients
undergoing curative-intent hepatic surgery, those who achieved R0
resection and those who did not undergo curative-intent surgery
are shown in Figure 1.
Patients with metastatic disease confined to the liver;
resection rate
In the sub-population of patients with liver-only metastatic disease
(n¼704), 107 patients (15.2%) underwent curative-intent hepatic
metastasectomy, which was a R0 resection in 85 out of 107 patients
(79.4%). It should be noted, however, that neither FIRST BEAT nor
NO16966 required formal multidisciplinary evaluation for resect-
ability before entrance; it is likely that a portion of these patients
Table 1 Baseline characteristics of patients enrolled in the First BEAT
and NO16966 trials
First BEAT trial
(n¼1914)
NO16966
FOLFOX or
XELOX + placebo
(n¼701)
FOLFOX or
XELOX +
bevacizumab
(n¼699)
Sex (%)
Male 58 56 60
Female 42 44 40
Age
Median 59 60 (FOLFOX/placebo) 60 (FOLFOX/bev)
61 (XELOX/placebo) 61 (XELOX/bev)
ECOG PS (%)
06 5 6 0 5 8
13 4 4 0 4 1
Primary tumour site (%)
Colon 62 66 66
Rectum 27 26 26
Colon and
rectum
11 8 9
Previous adjuvant therapy (%)
Yes 38 25 23
No 62 75 77
Number of metastatic sites (%)
16 1 4 2 4 1
413 9 5 75 9
Abbreviations: BEAT¼bevacizumab expanded access trial; ECOG¼Eastern Cooperative
Oncology Group; FOLFOX4¼5-FU and oxaliplatin; XELOX¼capecitabine plus
oxaliplatin.
Table 2 Patients undergoing resections within the First BEAT and N016966
trials
No. of patients
undergoing
surgery with
curative intent
(%)
No. of patients
undergoing R0
resection (%)
% Of curative-
intent
resections
that were R0
Hepatic
resections
with curative
intent (%)
R0 hepatic
resections
(%)
% Of hepatic
resections
that were R0
First BEAT
All evaluable patients (ITT population) n¼1914 225 (11.8%) 173 (9.0) 76.9 145 (7.6) 114 (6.0) 78.6
Patients receiving oxaliplatin-based chemotherapy n¼949 153 (16.1) 116 (12.2) 75.8 99 (10.4) 76 (8.0) 76.8
Patients receiving irinotecan-based chemotherapy n¼662 64 (9.7) 49 (7.4) 76.6 43 (6.5) 34 (5.1) 79.1
NO16966
XELOX or FOLFOX4 + bevacizumab n¼699 59 (8.4) 44 (6.3) 74.6 — — —
XELOX or FOLFOX4 + placebo n¼701 43 (6.1) 34 (4.9) 79.1 — — —
Abbreviations: BEAT¼bevacizumab expanded access trial; FOLFOX4¼5-FU and oxaliplatin; ITT¼intention to treat; XELOX¼capecitabine plus oxaliplatin.
Months from commencing treatment
All patients evaluable at cut off (n=1914)
Hepatic metastasectomy and R0 resection (n=114)
Hepatic metastasectomy total (n=145)
No hepatic metastasectomy (n=1769)
OS at 24 months
89%
86%
47%
P<0.0001
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Figure 1 Kaplan–Meier estimate for overall survival in patients under-
going curative-intent hepatic resection, curative hepatic resection with no
residual disease (R0) and the remainder of the intention to treat (ITT)
population in First bevacizumab expanded access trial (BEAT).
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swould have been deemed resectable from the outset at some
specialised centres.
Table 3 shows the exploratory comparison of resection rate
in the subgroups of patients with liver-only metastases treated
with oxaliplatin or irinotecan based chemotherapy. Curative-
intent hepatic resection rate was higher in 350 patients treated
with oxaliplatin-based combination chemotherapy (71 out of 350
patients; 20.3%) than in those treated with irinotecan combination
chemotherapy (33 out of 230patients; 14.5%) although the
difference did not reach statistical significance (P¼0.077).
Patients with metastatic disease confined to the liver OS
OS was significantly longer in patients who underwent hepatic
resections compared with those who did not (log rank Po0.001).
The OS for all patients with liver-only disease within First-BEAT
was 25.2 months and has not yet been reached in those undergoing
curative-intent metastasectomy. The 2-year OS rate in all patients
with liver-only disease is 54%, compared with 89% in patients
undergoing curative-intent resection and 94% in those who
achieved R0 resection. The Kaplan–Meier survival curves for
patients with liver-only disease undergoing R0 resection vs those
who did not are shown in Figure 2.
NO16966
Baseline characteristics for the ITT population are summarised in
Table 1.
Resection rate
In the ITT population (n¼1400), 44 out of 699 (6.3%) patients
receiving bevacizumab plus chemotherapy underwent curative
(R0) resection, compared with 34 out of 701 (4.9%) patients
receiving chemotherapy plus placebo, however, this difference was
not statistically significant (P¼0.24). Similarly, when analyzing
the subgroup of patients with liver-only disease at baseline, 26 out
of 211 (12.3%) patients of those receiving bevacizumab underwent
curative surgery compared with 24 out of 207 (11.6%) patients
receiving placebo (P¼0.81). These data are summarised in
Tables 2 and 3.
Overall survival
Of the 78 patients undergoing R0 resection within the trial, 2-year
OS was not statistically different in patients receiving bevacizumab
(90.9%), compared with those receiving placebo (82.3%). Two-year
OS in patients not undergoing R0 resection was 39.6% in patients
receiving bevacizumab and 37.9% in those randomised to
chemotherapy plus placebo.
Safety
Table 4 shows bevacizumab related grade 3/4 adverse events for
patients treated within NO16966 and First BEAT, and specific
surgical complications that were prospectively collected from
patients undergoing curative-intent resections in First BEAT. It
should be noted that there were no surgery-related deaths (deaths
due to events that developed within 30 days of surgery).
DISCUSSION
First BEAT prospectively collected safety data from patients
undergoing surgery and is the largest data set using a targeted
agent in this setting. Data from the randomised phase-III NO16966
trial were collected retrospectively, therefore, must be interpreted
with more caution.
First BEAT reported a 6% R0 hepatic resection rate in the
unselected population and 12.1%, when selecting patients with
liver-only disease. In the NO16966 study, there was no significant
difference in R0 resection rate in patients treated with
bevacizumab compared with placebo (6.3 vs 4.9%, P¼0.24). A
major limitation of the analysis of resection rate in both studies is
that resectability was not prospectively defined. It is conceivable
that some patients may have had resectable disease from the
outset, especially if reviewed by an experienced hepatobiliary
surgeon at a tertiary referral centre.
The optimal regimen for patients with potentially resectable
disease is yet to be defined, but a strong correlation between
response to chemotherapy and subsequent resection rate has
been described (Folprecht et al, 2005). An exploratory subgroup
Table 3 Patients with liver-only disease within the First BEAT and NO16966 trials
All patients undergoing
hepatic resection (%)
Curative-intent hepatic
resections (%)
R0 hepatic
resections (%)
First BEAT
All patients with liver-only disease n¼704 132 (18.8%) 107 (15.2%) 85 (12.1%)
Patients receiving oxaliplatin-based chemotherapy n¼350 85 (24.3%) 71 (20.3%) 54 (15.4%)
Patients receiving irinotecan-based chemotherapy n¼230 43 (18.7%) 33 (14.3%) 27 (11.7%)
NO16966
XELOX or FOLFOX4 + bevacizumab n¼211 26 (12.3)
XELOX or FOLFOX4 + placebo n¼207 24 (11.6)
Abbreviations: BEAT¼bevacizumab expanded access trial; FOLFOX4¼5-FU and oxaliplatin; XELOX¼capecitabine plus oxaliplatin.
Months from commencing treatment
Patients with metastatic disease limited to the liver at baseline (n=704)
Hepatic metastasectomy and R0 resection (n=85)
No R0 hepatic metastasectomy (n=619)
OS at 24 months
95%
54% P<0.0001
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Figure 2 Kaplan–Meier survival curves for all patients with liver-only
disease undergoing R0 hepatic resections vs those with liver only disease
that did not in First bevacizumab expanded access trial (BEAT).
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sanalysis of the First BEAT data demonstrated that a higher
proportion of patients treated with bevacizumab plus oxaliplatin-
based chemotherapy than bevacizumab plus an irinotecan-based
regimen underwent curative-intent surgery (16.1% vs 9.7%).
However, the resection rate within the oxaliplatin-treated sub-
group in First BEAT is substantially higher than seen in N016966,
which could suggest that First BEAT investigators chose to use
oxaliplatin-based regimens in patients with potentially resectable
disease. There are also differences in the baseline characteristics of
the patient populations of each study, which may have contributed
to the difference in resection rates. For example, more patients in
First BEAT had a single site of metastatic disease (61% compared
with 41 and 42% in the bevacizumab and placebo arms,
respectively).
In First BEAT, overall survival was longer in patients who
underwent hepatic metastasectomy compared with those who did
not. A limitation of this comparison is that at the start of
treatment, all patients received chemotherapy, and therefore there
were no patients in the surgery group. Hence, the estimates and
comparisons are biased, as patients who eventually underwent
surgery have an initial guaranteed survival time.
Although bevacizumab improved the response rate when added
to IFL (Hurwitz et al, 2004), which has since been superseded by
the FOLFIRI regimen, it did not improve the response at all when
added to XELOX or FOLFOX (Saltz et al, 2008). Thus, although the
choice of chemotherapy regimen may be key to maximising
resection rate with bevacizumab combinations, the choice to be
made is unclear. A superior response rate has been reported with
the FOLFOXIRI regimen (66% vs 41% with FOLFIRI) in the first-
line setting, with a corresponding increase in R0 resection rate,
reported as 36% in a subgroup of patients with liver-only
metastatic disease (Falcone et al, 2007). However, a second
phase-III trial of the regimen reported a more modest response
rate of 43% from the combination (33.6% with FOLFIRI), possibly
due to the lower doses of all three agents used.
An apparent increase in steatohepatitis and a subsequently
increased 90-day mortality after liver resection has been reported
with irinotecan given before liver surgery (Vauthey et al, 2006).
Oxaliplatin is also known to affect the liver, causing sinusoidal
dilatation in 19% of cases in the same series (Vauthey et al,
2006). It is interesting to note that in a retrospective series of 105
patients treated with oxaliplatin-based chemotherapy with or
without bevacizumab, the investigators reported a lower incidence
and severity of sinusoidal dilatation in patients receiving
bevacizumab (Po0.01) (Ribero et al, 2007). The authors suggested
that this may be because of VEGF blockade-mediated down-
regulation of matrix-metalloproteinase-9, which is known to be
involved in sinusoidal dilatation. A recently published non-
randomised phase-II study of bevacizumab with capecitabine
and oxaliplatin in 56 patients with potentially resectable liver
metastases reported one case of abnormal liver function/regenera-
tion due to steatohepatitis, (Gruenberger et al, 2008) which
is consistent with the observation that major perturbations in
liver function or liver regeneration with chemotherapy of moderate
duration are rare.
The optimal timing of surgery after chemotherapy alone is
again unresolved. In the EORTC Intergroup Trial 40983, surgery
was planned for 2–5 weeks after the last administration of
chemotherapy and took place a median of 4.1 weeks after
chemotherapy (range 2–16.4 weeks) (Nordlinger et al, 2008).
Reversible peri-operative complications were more frequent in the
chemotherapy arm (25% vs 16%, P¼0.04) with notable increases
in biliary fistulae, hepatic failure and intra-abdominal infections,
but no difference in bleeding, venous thromboembolism or post-
operative death rates. Whether the increase in complications
related to the timing of surgery relative to chemotherapy, or
simply the exposure to chemotherapy itself, cannot be determined
from these data, although data from a retrospective series of
750 patients undergoing hepatic resection, suggest that the rate of
complications is highest in patients undergoing surgery within
4 weeks of chemotherapy (Welsh et al, 2007).
More caution is generally applied when bevacizumab is used
before or after surgery because of potential effects on bleeding,
wound-healing and liver regeneration. In an analysis of pooled
data from two randomised studies, the reported wound-healing
complication rate after an unplanned major surgery during
treatment was 13% for patients treated with 5-FU and bevacizu-
mab compared with 3.4% in patients treated with chemotherapy
alone (Scappaticci et al, 2005). However, in patients that had
undergone major surgery 28–60 days before commencing
bevacizumab, a significant difference in wound-healing complica-
tions was not observed in the bevacizumab and control arms (1.3%
vs 0.5%) (Scappaticci et al, 2005), suggesting that the risk of this
complication can be reduced by careful management of the timing
of surgery in relation to bevacizumab. In First BEAT, surgery took
place at a median of 64 days after the last dose of bevacizumab,
which could be considered as a conservative approach, but was
associated with a relatively low rate of serious complications.
Results from a small, non-randomised study suggests that a
shorter time period between bevacizumab and surgery may be
reasonable; this phase-II trial using a 5-week delay reported a
21% total complications rate after liver surgery (less than reported
in the EORTC 40983 trial (Nordlinger et al, 2008)), with blood
transfusions required in 6% of the patients and no peri-operative
mortality (Gruenberger et al, 2008).
There are fewer safety concerns with the addition of the EGFR
monoclonal antibody, cetuximab, to neo-adjuvant chemotherapy.
Data from a pre-planned analysis in the phase-III CRYSTAL trial
demonstrated potential efficacy of adding cetuximab to downsize
initially unresectable disease, with R0 resections achieved in 4.3%
of patients treated with FOLFIRI plus cetuximab, compared with
1.5% in those treated with FOLFIRI alone (P¼0.0034) and 9.8% vs
4.5% R0 resections respectively, in an exploratory subgroup
analysis of patients with liver-only disease (Van Cutsem et al,
Table 4 Grade 3/4 bevacizumab-related serious adverse events in NO16966 and First BEAT and surgical complications in resected patients in First BEAT
Bleeding
Wound healing
complications GI perforation Hypertension
Arterial
thrombo-embolism
NO16966
FOLFOX4 or XELOX + placebo (n¼675) 8 (1.2%) 2 (0.3%) 2 (0.3%) 8 (1.2%) 7 (1.0%)
FOLFOX4 or XELOX + bevacizumab (n¼694) 13 (1.9%) 1 (0.1%) 4 (0.6%) 26 (3.7%) 12 (1.7%)
First BEAT (ITT population n¼1914) 61 (3.2%) 20 (1.0%) 34 (1.8%) 97 (5.1%) 24 (1.3%)
First BEAT
Surgical complications in patients undergoing
curative-intent metastasectomy (n¼225)
1 (0.4%)
Any grade:
3 (1.3%)
4 (1.8%)
Any grade:
11 (4.9%)
5 (2.2%) 16 (7.1%) 3 (1.3%)
Abbreviations: BEAT¼bevacizumab expanded access trial; FOLFOX4¼5-FU and oxaliplatin; ITT¼intention to treat; XELOX¼capecitabine plus oxaliplatin.
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those reported here, however, the resection rates in the
chemotherapy arm alone are notably lower than in the placebo
arm of NO16966 (4.9% of the ITT population, 11.6% of patients
with liver-only disease), possibly due to the different cytotoxic
chemotherapy regimens. It should be noted that cetuximab has
recently been recommended by the UK National Institute for
Clinical Excellence (NICE) for use in combination with FOLFOX or
FOLFIRI in patients with K-ras wild-type and unresectable, liver-
only mCRC.
CONCLUSIONS
T h er a t eo fs e r i o u sp o s t - o p e r a t i v ec o m p l i c a t i o n si nF i r s tB E A Tw a s
acceptable, with resection rates consistent with those reported in the
recent literature. The contribution of bevacizumab is difficult to
evaluate outside a randomised controlled trial. In NO16966, there was
no statistically significant difference in resection rate or the OS in
patients treated with bevacizumab vs placebo, however, the numbers of
patients undergoing resection in thist r i a lw a ss m a l l ;t h u st h ea b i l i t yo f
this trial to detect a difference in resection rates would be quite limited.
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